Navigation Links
Maker of VSL#3 probiotic offers assistance program for ulcerative colitis and ileal pouch patients

GAITHERSBURG, MD, January 31 People who have Ulcerative Colitis (UC) or Ileal Pouch know that finding the right regimen for extending their time between flares is crucial to successfully living with the condition. The solution is often a personalized combination of drugs, dietary changes and, for many, the addition of VSL#3, a probiotic medical food designated for the dietary management of these conditions. Now, Sigma-Tau Pharmaceuticals, Inc., maker of VSL#3 medical food is sponsoring a Patient Assistance Program (PAP) to help in-need patients obtain its prescription-only double strength formulation VSL#3 DS.

The VSL#3 DS Patient Assistance Program is one of the first to provide assistance for a probiotic preparation. Sigma-Tau created this program in reaction to patient response to the product.

"We hear from many patients that VSL#3 DS is integral in the routine they adhere to in order to manage their diets," said Mary Berry, senior product manager at Sigma-Tau. "While this product is covered as a Tier 3 co-pay in many prescription plans, there are still many patients who do not have coverage and cannot afford to keep using it. We want to change that and make sure people who depend on VSL#3 DS can obtain it."

VSL#3 stands apart from other probiotics since it is not a supplement it is a refrigerated medical food. It is one of the few probiotic preparations supported by Level 1 (double-blind, placebo-controlled) scientific data, and has been the subject of a collection of more than 80 studies that have demonstrated its application in the dietary management of IBS, Ulcerative Colitis, and Ileal Pouch.

VSL#3 DS delivers 900 billion bacteria per packet (up to 22.5 times more potent than the average probiotic) and consists of 8 strains of live, freeze-dried lactic acid bacteria. It is the only probiotic recognized as an effective tool in the dietary management of ileal pouch by the American College of Gastroenterology1 and by the Cochrane Review2.

The VSL#3 DS PAP varies with each patient depending on individual evaluation. The eligibility criteria for this program is that the patient must have an applicable diagnosis or physician referral, be a legal U.S. resident, and must meet a financial need criteria.

Decisions for coverage are usually announced within two business days after applying. The product is shipped directly to the patient, and one can reapply for assistance every November to ensure continued supply of the probiotic.

Contact: Nicole Egan
Robin Leedy & Associates, Inc.

Related biology news :

1. A new species of gall makers in the aphid genus of plant lice was found in China
2. Sea squirt pacemaker gives new insight into evolution of the human heart
3. What motivates environmental activists, policymakers? asks new research center
4. Filmmakers Joel and Ethan Coen among 2011 Dan David Prize winners
5. Brupbacher Prize goes to B. Vogelstein and J. Hoeijmakers for research on colorectal and skin cancer
6. Ocean fertilization summary for policymakers published
7. Oil spill symposium to convene scientists, media, policymakers and community leaders
8. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
9. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
10. New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports
11. Global Rainmakers Delivers World Class Iris Capability for Portoss
Post Your Comments:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: